NCT01843972View on ClinicalTrials.gov

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Healthy
Interventions
DRUG

BI 691751

oral solution BI 691751, dose 6

DRUG

BI 691751

oral solution

DRUG

Placebo

placebo solution

DRUG

BI 691751

oral solution BI 691751, dose 2

DRUG

BI 691751

oral solution BI 691751, dose 5

DRUG

BI 691751

1 tablet

DRUG

BI 691751

oral solution BI 691751, dose 3

DRUG

BI 691751

oral solution BI 69175, dose 4

DRUG

BI 691751

oral solution BI 691751, dose 7

DRUG

BI 691751

oral solution BI 69175, dose 1

Trial Locations (1)

Unknown

1334.1.1 Boehringer Ingelheim Investigational Site, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01843972 - Safety of Single Rising Doses and Relative Bioavailability of BI 691751 | Biotech Hunter | Biotech Hunter